Critical Analysis: Provectus Biopharmaceuticals (OTCMKTS:PVCT) & Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Earnings and Valuation

This table compares Illumina and Provectus Biopharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.29 billion	5.08	-$1.22 billion	$4.46	31.99
Provectus Biopharmaceuticals	$620,000.00	40.33	-$4.76 million	N/A	N/A

Provectus Biopharmaceuticals has lower revenue, but higher earnings than Illumina.

Risk and Volatility

Illumina has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Illumina and Provectus Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2	14	5	0	2.14
Provectus Biopharmaceuticals	0	0	0	0	0.00

Illumina presently has a consensus target price of $122.56, suggesting a potential downside of 14.10%. Given Illumina’s stronger consensus rating and higher probable upside, research analysts clearly believe Illumina is more favorable than Provectus Biopharmaceuticals.

Insider and Institutional Ownership

89.4% of Illumina shares are owned by institutional investors. Comparatively, 0.1% of Provectus Biopharmaceuticals shares are owned by institutional investors. 2.6% of Illumina shares are owned by insiders. Comparatively, 14.7% of Provectus Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Illumina and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Illumina	16.40%	29.21%	11.07%
Provectus Biopharmaceuticals	-1,374.19%	N/A	-942.72%

Summary

Illumina beats Provectus Biopharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.